

July 2022

medical benefit specialty drug update **bulletin**

Specialty Drug Program Updates for UnitedHealthcare Commercial, Community Plan, Medicare Advantage, and Individual & Family Plans

Review the following tables to determine changes to our specialty medical injectable drug programs.

SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO REVIEW AT LAUNCH

Drug Name	UnitedHealthcare Commercial	UnitedHealthcare Community Plan	UnitedHealthcare Medicare Advantage	UnitedHealthcare Individual & Family	Treatment Uses
Amvuttra™ (vutrisiran)	X	X	X	X	Indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.



To view the **UnitedHealthcare Commercial Plan** Review at Launch Medication List, go to UHCprovider.com > Policies and Protocols > Commercial Policies > Medical & Drug Policies and Coverage Determination Guidelines for UnitedHealthcare Commercial Plans > *Review at Launch for New to Market Medications* > [Review at Launch Medication List](#).

To view the **UnitedHealthcare Community Plan** Review at Launch Drug List Plan, go to UHCprovider.com > Policies and Protocols > Community Plan Policies > Medical & Drug Policies and Coverage Determination Guidelines for Community Plan > *Review at Launch for New to Market Medications* > [Review at Launch Medication List](#).

For **UnitedHealthcare Medicare Advantage**, Review at Launch drugs are added as Review at Launch Part B Medications in the *Medications/Drugs (Outpatient/Part B) Coverage Summary*. To view the summary, go to UHCprovider.com > Policies and Protocols > Medicare Advantage Policies > Coverage Summaries for Medicare Advantage Plans > [Medications/Drugs \(Outpatient/Part B\) – Medicare Advantage Coverage Summary](#) > *Attachment A: Guideline 5 – Other Examples of Specific Drugs/Medications*.

To view the **UnitedHealthcare Individual & Family Plan** Review at Launch Medication List, go to UHCprovider.com > Policies and Protocols > For Exchange Plans > Medical & Drug Policies and Coverage Determination Guidelines for UnitedHealthcare Individual Exchange Plans > *Review at Launch for New to Market Medications* > [Review at Launch Medication List](#)

UPDATES TO DRUG PROGRAM REQUIREMENTS AND DRUG POLICIES

Drug Name	Effective Date	UnitedHealthcare Commercial	UnitedHealthcare Community Plan	UnitedHealthcare Medicare Advantage	UnitedHealthcare Individual & Family	Treatment Uses	Summary of Changes
Botulinum toxins A and B - Dysport®, Xeomin®, Botox®, Myobloc®	10/1/22			X		Neuromuscular blocker/acetylcholine release inhibitor used in many neurological, neuromuscular, and urological conditions such as migraine, spasticity, strabismus, torticollis, urinary incontinence, and overactive bladder.	<ul style="list-style-type: none"> Add notification/prior authorization
Enjaymo™ (sutimlimab-jome)	10/1/22	X	X	X	X	Decrease the need for red blood cell transfusion because of hemolysis in adults with cold agglutinin disease (CAD).	<ul style="list-style-type: none"> Add notification/prior authorization For Commercial, add Site of Care (SOC) & Medication Sourcing (MS)
Fylnetra™ (pegfilgrastim-pbbk)	10/1/22	X	X	X	X	Indicated to prevent febrile neutropenia in individuals receiving chemotherapy.	<ul style="list-style-type: none"> Add notification/prior authorization For Commercial, Community Plan, and Individual & Family, add preferred product – Fylnetra™ is non-preferred; Neulasta® and Ziextenzo are preferred®
Immune Globulins	10/1/22			X		Indicated for the treatment of a variety of immune deficiencies, autoimmune diseases, and neuroimmunologic disorders.	<ul style="list-style-type: none"> Add notification/prior authorization
Korsuva™ (difelikefalin)	10/1/22	X	X	X	X	Moderate to severe itching associated with chronic kidney disease in adults undergoing hemodialysis.	<ul style="list-style-type: none"> Add notification/prior authorization

							<ul style="list-style-type: none"> For Commercial, will be managed by Kidney Resource Services (KRS)
Releuko® (filgrastim-ayow)	10/1/22	X	X	X	X	Indicated to decrease the incidence of infection, as manifested by febrile neutropenia.	<ul style="list-style-type: none"> Add notification/prior authorization For Commercial, Community Plan, and Individual & Family, add preferred product – Releuko® is non-preferred; Zarxio® is preferred
Scenesse® (afamelanotide)	10/1/22		X Texas only			To increase pain free light exposure in patients with erythropoietic protoporphyria (EPP) and a history of phototoxic reactions	<ul style="list-style-type: none"> Add notification/prior authorization
Tezspire™ (tezepelumab-ekko)	10/1/22	X	X	X	X	Add on maintenance treatment of severe asthma in adults and children 12 years and older.	<ul style="list-style-type: none"> Add notification/prior authorization For Commercial, add SOC & MS For Commercial, add as non-preferred product for treatment naïve patients with eosinophilic asthma type, requiring trial and failure of both of the following: 1.) Nucala or Fasenra® and 2.) Dupixent®
Vabysmo® (faricimab-svoa)	10/1/22				X	For the treatment of Neovascular (wet) age-related macular degeneration (AMD) and macular edema.	<ul style="list-style-type: none"> Add notification/prior authorization

Upon prior authorization renewal, the updated policy will apply. UnitedHealthcare will honor all approved prior authorizations on file until the end date on the authorization or the date the member's eligibility changes. You don't need to submit a new notification/prior authorization request for members who already have an authorization for these medications on the effective date noted above.



Note: Certain specialty medical injectable drug programs and updates will not be implemented at this time for providers practicing in Rhode Island, with respect to certain commercial members, pursuant to the Rhode Island regulation: 230 -RICR-20-30-14. UnitedHealthcare encourages providers practicing in Rhode Island to call in to confirm if prior authorization is required. This exception does not apply to Medicaid and Medicare.

New and Updated Procedure Codes for Injectable Medications – Effective July 1st, 2022

Effective July 1, 2022, new procedure codes were created for certain drugs due to updates from the Centers for Medicare & Medicaid Services (CMS). Correct coding rules dictate that assigned and permanent codes should be used when available. The following injectable medications will have new codes:

- **Apretude™** (cabotegravir extended-release injectable suspension) – J0739
- **Carvykti™** (ciltacabtagene autoleucel) – C9098
- **Cutaquig®** (immune globulin subcutaneous (human) – hipp) – J1551
- **Enjaymo™** (sutimlimab-jome) – C9094
- **Leqvio®** (inclisiran) – J1306
- **Releuko®** (filgrastim-ayow) – C9096
- **Ryplazim®** (plasminogen, human-tvmh) – J2998
- **Susvimo™** (ranibizumab) – J2779
- **Tezspire™** (tezepelumab-ekko) – J2356
- **Vabysmo®** (faricimab-svoa) – C9097
- **Vyvgart™** (efgartigimod) – J9332